Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprote...
Gespeichert in:
| Veröffentlicht in: | Diabetologia 2024-06, Vol.67 (6), p.974-984 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 984 |
|---|---|
| container_issue | 6 |
| container_start_page | 974 |
| container_title | Diabetologia |
| container_volume | 67 |
| creator | Béliard, Sophie Mourre, Florian Valéro, René |
| description | Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprotein convertase subtilisin/kexin 9 (PCSK9) antibodies; an siRNA targeting PCSK9; bempedoic acid, which targets ATP citrate lyase; an antisense oligonucleotide targeting apolipoprotein C-III; an anti-angiopoietin-like 3 antibody; and a purified omega-3 fatty acid, icosapent ethyl. Other therapies are in different phases of development. There are several important considerations concerning the link between these new lipid-lowering therapies and diabetes. First, since concerns were first raised in 2008 about an increased risk of new-onset diabetes mellitus (NODM) with intensive statin treatment, each new lipid-lowering therapy is being evaluated for its associated risk of NODM, particularly in individuals with prediabetes (impaired fasting glucose and/or impaired glucose tolerance). Second, people with diabetes represent a large proportion of those at high or very high cardiovascular risk in whom these lipid-lowering drugs are currently, or will be, prescribed. Thus, the efficacy of these drugs in subgroups with diabetes should also be closely considered, as well as any potential effects on glycaemic control. In this review, we describe the efficacy of next-generation therapies targeting lipoprotein metabolism in subgroups of people with diabetes and their effects on glycaemic control in individuals with diabetes and prediabetes and in normoglycaemic individuals.
Graphical Abstract |
| doi_str_mv | 10.1007/s00125-024-06100-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11058750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2928852835</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-2c7151ff8989712bdaaff34eaaaf3f865abbc4ff1c54ecf6b8bf9cae0bce920c3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhC3BAkbjAITD-lzhcqqoCFmklLiBxsxxnvOsq6wQ7qdp-erzNUqAHLrY183tvbD9CXlJ4RwHq9wmAMlkCEyVUuVLePiIrKjgrQTD1mKwO_ZKq6scJeZbSJQBwKaqn5IQrXleSVyui1zcjxt6PvjO496bwoei8aXHC9KEwEYtph3kdTZy8nXsTCzuE5DuMZvL5VLghFgGvp3KL4Vi805jRYzp7Tp440yd8cdxPyfdPH79drMvN189fLs43pRUVTCWzNZXUOdWopqas7Yxxjgs0eedOVdK0rRXOUSsFWle1qnWNNQitxYaB5afkbPEd53aPncUwRdPrMfq9iTd6MF7_2wl-p7fDlaYUpKolZIe3i8PugW59vtGHGghZCybYFc3sm-O0OPycMU1675PFvjcBhzlp1jClJFNcZvT1A_RymGPIf6E5CMWYkJRnii2UjUNKEd39DSjoQ9h6CVvnsPVd2Po2i179_eZ7ye90M8AXIOVW2GL8M_s_tr8AeDC4bw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3048224513</pqid></control><display><type>article</type><title>Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Béliard, Sophie ; Mourre, Florian ; Valéro, René</creator><creatorcontrib>Béliard, Sophie ; Mourre, Florian ; Valéro, René</creatorcontrib><description>Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprotein convertase subtilisin/kexin 9 (PCSK9) antibodies; an siRNA targeting PCSK9; bempedoic acid, which targets ATP citrate lyase; an antisense oligonucleotide targeting apolipoprotein C-III; an anti-angiopoietin-like 3 antibody; and a purified omega-3 fatty acid, icosapent ethyl. Other therapies are in different phases of development. There are several important considerations concerning the link between these new lipid-lowering therapies and diabetes. First, since concerns were first raised in 2008 about an increased risk of new-onset diabetes mellitus (NODM) with intensive statin treatment, each new lipid-lowering therapy is being evaluated for its associated risk of NODM, particularly in individuals with prediabetes (impaired fasting glucose and/or impaired glucose tolerance). Second, people with diabetes represent a large proportion of those at high or very high cardiovascular risk in whom these lipid-lowering drugs are currently, or will be, prescribed. Thus, the efficacy of these drugs in subgroups with diabetes should also be closely considered, as well as any potential effects on glycaemic control. In this review, we describe the efficacy of next-generation therapies targeting lipoprotein metabolism in subgroups of people with diabetes and their effects on glycaemic control in individuals with diabetes and prediabetes and in normoglycaemic individuals.
Graphical Abstract</description><identifier>ISSN: 0012-186X</identifier><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-024-06100-z</identifier><identifier>PMID: 38376536</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Angiopoietin ; Antisense oligonucleotides ; Antisense therapy ; Apolipoprotein C-III ; ATP citrate lyase ; Cardiovascular diseases ; Chylomicrons ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Glucose tolerance ; High density lipoprotein ; Human Physiology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hyperlipidemia ; Hyperlipidemias - drug therapy ; Hypolipidemic Agents - therapeutic use ; Immunological tolerance ; Internal Medicine ; Kexin ; Life Sciences ; Lipid metabolism ; Lipids ; Lipoproteins (very low density) ; Low density lipoprotein ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metabolism ; Omega-3 fatty acids ; Proprotein convertases ; Review ; Risk factors ; siRNA ; Subtilisin</subject><ispartof>Diabetologia, 2024-06, Vol.67 (6), p.974-984</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c460t-2c7151ff8989712bdaaff34eaaaf3f865abbc4ff1c54ecf6b8bf9cae0bce920c3</cites><orcidid>0000-0002-2176-3280 ; 0000-0003-3695-4095 ; 0000-0002-6000-5028</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00125-024-06100-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00125-024-06100-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38376536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://amu.hal.science/hal-04574242$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Béliard, Sophie</creatorcontrib><creatorcontrib>Mourre, Florian</creatorcontrib><creatorcontrib>Valéro, René</creatorcontrib><title>Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><addtitle>Diabetologia</addtitle><description>Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprotein convertase subtilisin/kexin 9 (PCSK9) antibodies; an siRNA targeting PCSK9; bempedoic acid, which targets ATP citrate lyase; an antisense oligonucleotide targeting apolipoprotein C-III; an anti-angiopoietin-like 3 antibody; and a purified omega-3 fatty acid, icosapent ethyl. Other therapies are in different phases of development. There are several important considerations concerning the link between these new lipid-lowering therapies and diabetes. First, since concerns were first raised in 2008 about an increased risk of new-onset diabetes mellitus (NODM) with intensive statin treatment, each new lipid-lowering therapy is being evaluated for its associated risk of NODM, particularly in individuals with prediabetes (impaired fasting glucose and/or impaired glucose tolerance). Second, people with diabetes represent a large proportion of those at high or very high cardiovascular risk in whom these lipid-lowering drugs are currently, or will be, prescribed. Thus, the efficacy of these drugs in subgroups with diabetes should also be closely considered, as well as any potential effects on glycaemic control. In this review, we describe the efficacy of next-generation therapies targeting lipoprotein metabolism in subgroups of people with diabetes and their effects on glycaemic control in individuals with diabetes and prediabetes and in normoglycaemic individuals.
Graphical Abstract</description><subject>Angiopoietin</subject><subject>Antisense oligonucleotides</subject><subject>Antisense therapy</subject><subject>Apolipoprotein C-III</subject><subject>ATP citrate lyase</subject><subject>Cardiovascular diseases</subject><subject>Chylomicrons</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Glucose tolerance</subject><subject>High density lipoprotein</subject><subject>Human Physiology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hyperlipidemia</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Immunological tolerance</subject><subject>Internal Medicine</subject><subject>Kexin</subject><subject>Life Sciences</subject><subject>Lipid metabolism</subject><subject>Lipids</subject><subject>Lipoproteins (very low density)</subject><subject>Low density lipoprotein</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Metabolism</subject><subject>Omega-3 fatty acids</subject><subject>Proprotein convertases</subject><subject>Review</subject><subject>Risk factors</subject><subject>siRNA</subject><subject>Subtilisin</subject><issn>0012-186X</issn><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EokvhC3BAkbjAITD-lzhcqqoCFmklLiBxsxxnvOsq6wQ7qdp-erzNUqAHLrY183tvbD9CXlJ4RwHq9wmAMlkCEyVUuVLePiIrKjgrQTD1mKwO_ZKq6scJeZbSJQBwKaqn5IQrXleSVyui1zcjxt6PvjO496bwoei8aXHC9KEwEYtph3kdTZy8nXsTCzuE5DuMZvL5VLghFgGvp3KL4Vi805jRYzp7Tp440yd8cdxPyfdPH79drMvN189fLs43pRUVTCWzNZXUOdWopqas7Yxxjgs0eedOVdK0rRXOUSsFWle1qnWNNQitxYaB5afkbPEd53aPncUwRdPrMfq9iTd6MF7_2wl-p7fDlaYUpKolZIe3i8PugW59vtGHGghZCybYFc3sm-O0OPycMU1675PFvjcBhzlp1jClJFNcZvT1A_RymGPIf6E5CMWYkJRnii2UjUNKEd39DSjoQ9h6CVvnsPVd2Po2i179_eZ7ye90M8AXIOVW2GL8M_s_tr8AeDC4bw</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Béliard, Sophie</creator><creator>Mourre, Florian</creator><creator>Valéro, René</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2176-3280</orcidid><orcidid>https://orcid.org/0000-0003-3695-4095</orcidid><orcidid>https://orcid.org/0000-0002-6000-5028</orcidid></search><sort><creationdate>20240601</creationdate><title>Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?</title><author>Béliard, Sophie ; Mourre, Florian ; Valéro, René</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-2c7151ff8989712bdaaff34eaaaf3f865abbc4ff1c54ecf6b8bf9cae0bce920c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Angiopoietin</topic><topic>Antisense oligonucleotides</topic><topic>Antisense therapy</topic><topic>Apolipoprotein C-III</topic><topic>ATP citrate lyase</topic><topic>Cardiovascular diseases</topic><topic>Chylomicrons</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Glucose tolerance</topic><topic>High density lipoprotein</topic><topic>Human Physiology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hyperlipidemia</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Immunological tolerance</topic><topic>Internal Medicine</topic><topic>Kexin</topic><topic>Life Sciences</topic><topic>Lipid metabolism</topic><topic>Lipids</topic><topic>Lipoproteins (very low density)</topic><topic>Low density lipoprotein</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Metabolism</topic><topic>Omega-3 fatty acids</topic><topic>Proprotein convertases</topic><topic>Review</topic><topic>Risk factors</topic><topic>siRNA</topic><topic>Subtilisin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Béliard, Sophie</creatorcontrib><creatorcontrib>Mourre, Florian</creatorcontrib><creatorcontrib>Valéro, René</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Béliard, Sophie</au><au>Mourre, Florian</au><au>Valéro, René</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?</atitle><jtitle>Diabetologia</jtitle><stitle>Diabetologia</stitle><addtitle>Diabetologia</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>67</volume><issue>6</issue><spage>974</spage><epage>984</epage><pages>974-984</pages><issn>0012-186X</issn><eissn>1432-0428</eissn><abstract>Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprotein convertase subtilisin/kexin 9 (PCSK9) antibodies; an siRNA targeting PCSK9; bempedoic acid, which targets ATP citrate lyase; an antisense oligonucleotide targeting apolipoprotein C-III; an anti-angiopoietin-like 3 antibody; and a purified omega-3 fatty acid, icosapent ethyl. Other therapies are in different phases of development. There are several important considerations concerning the link between these new lipid-lowering therapies and diabetes. First, since concerns were first raised in 2008 about an increased risk of new-onset diabetes mellitus (NODM) with intensive statin treatment, each new lipid-lowering therapy is being evaluated for its associated risk of NODM, particularly in individuals with prediabetes (impaired fasting glucose and/or impaired glucose tolerance). Second, people with diabetes represent a large proportion of those at high or very high cardiovascular risk in whom these lipid-lowering drugs are currently, or will be, prescribed. Thus, the efficacy of these drugs in subgroups with diabetes should also be closely considered, as well as any potential effects on glycaemic control. In this review, we describe the efficacy of next-generation therapies targeting lipoprotein metabolism in subgroups of people with diabetes and their effects on glycaemic control in individuals with diabetes and prediabetes and in normoglycaemic individuals.
Graphical Abstract</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38376536</pmid><doi>10.1007/s00125-024-06100-z</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2176-3280</orcidid><orcidid>https://orcid.org/0000-0003-3695-4095</orcidid><orcidid>https://orcid.org/0000-0002-6000-5028</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-186X |
| ispartof | Diabetologia, 2024-06, Vol.67 (6), p.974-984 |
| issn | 0012-186X 1432-0428 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11058750 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Angiopoietin Antisense oligonucleotides Antisense therapy Apolipoprotein C-III ATP citrate lyase Cardiovascular diseases Chylomicrons Diabetes Diabetes mellitus Diabetes Mellitus - drug therapy Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Glucose tolerance High density lipoprotein Human Physiology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hyperlipidemia Hyperlipidemias - drug therapy Hypolipidemic Agents - therapeutic use Immunological tolerance Internal Medicine Kexin Life Sciences Lipid metabolism Lipids Lipoproteins (very low density) Low density lipoprotein Medicine Medicine & Public Health Metabolic Diseases Metabolism Omega-3 fatty acids Proprotein convertases Review Risk factors siRNA Subtilisin |
| title | Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A23%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperlipidaemia%20in%20diabetes:%20are%20there%20particular%20considerations%20for%20next-generation%20therapies?&rft.jtitle=Diabetologia&rft.au=B%C3%A9liard,%20Sophie&rft.date=2024-06-01&rft.volume=67&rft.issue=6&rft.spage=974&rft.epage=984&rft.pages=974-984&rft.issn=0012-186X&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-024-06100-z&rft_dat=%3Cproquest_pubme%3E2928852835%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3048224513&rft_id=info:pmid/38376536&rfr_iscdi=true |